Two Leading Labs Confirm Rhb-204 Map-Killing Effect - Nov 2

The Story

Two leading microbiology centers independently confirmed that RHB-204 kills Mycobacterium avium subspecies paratuberculosis in vitro, and reported that its MAP-killing activity is comparable to RedHill's RHB-104 in long-term intracellular culture and in spot and phage assays. The announcement is strictly about laboratory results and does not report clinical outcomes.

Why It Matters For Your Portfolio

• Independent validation: two outside labs confirmed in vitro MAP-killing, which strengthens the scientific case for RHB-204 and may influence how investors price RedHill's development-stage assets, including $RDHL.
• Quantified assay results: the briefing cites data points of 95.29%, 78.30% and 9.21%, providing multiple figures you can use in valuation models and scenario analysis for efficacy and market potential.
• Robust assay coverage: long-term intracellular culture plus spot and phage assays increase technical rigor, but absence of clinical data means execution risk remains and could keep near-term volatility elevated.
• Multiple data points available for valuation analysis, giving analysts inputs for upside and downside scenarios rather than relying on a single metric.

The Trade

Biotech and growth investors should watch for follow-up clinical readouts, regulatory steps and licensing updates that would move the story beyond in vitro validation. Traders may focus on any near-term press releases or peer comparisons, while long-term investors should track additional lab-to-clinic milestones and updated efficacy data. This information is for informational purposes only and not personalized investment advice.